Jeil Pharmaceutical’s new diabetes type I drug development selected as MOHW’s project

Published: 2017-09-26 16:28:00
Updated: 2017-09-26 16:42:29

‘JP -2266,’ a new oral diabetes type I drug being developed by Jeil Pharmaceutical(CEO/President Seok-Jae Sung), was selected as the Ministry of Health and Welfare’s high-tech medical technology development(new drug development support) project.

As being selected as a new supported project, ‘JP-...

Fees

- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.

Original Korean





TOP
BACK
Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.